LSD1 inhibitor programs
Iadademstat, its oncology/hematology program, is being evaluated in multiple Phase I and II clinical trials.
Source: LinkedIn company description · Retrieved October 13, 2026
Oryzon Genomics is a clinical-stage biopharmaceutical company focused on epigenetics and personalized medicine for central nervous system disorders and oncology/hematology.
Oryzon is headquartered in Barcelona, Spain, with a team across Barcelona, Boston, and New Jersey. Its clinical portfolio is built around two LSD1 inhibitors.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
Iadademstat, its oncology/hematology program, is being evaluated in multiple Phase I and II clinical trials.
Source: LinkedIn company description · Retrieved October 13, 2026
Vafidemstat is in clinical development across neuropsychiatric indications, including aggression in borderline personality disorder, negative symptoms of schizophrenia, and aggression in autism spectrum disorder, including genetically defined populations.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 4, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 15, 2026, September 16, 2026, September 19, 2026, September 27, 2026 and October 8, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.